A groundbreaking study led by the Institut de Neurociències at the Universitat Autònoma de Barcelona has shown that gene therapy can significantly elevate levels of the Klotho protein in mice, resulting in notable improvements in muscle strength, bone density, and cognitive performance, effectively reversing aging effects equivalent to 70 human years.

Published in Molecular Therapy and spearheaded by Professor Miguel Chillón, the research indicates that increasing the secreted form of Klotho protein (s-KL) can extend lifespan by 15 to 20% while also enhancing physical and cognitive aging.

To achieve these results, the study utilized a viral vector that was administered both intravenously and directly into the brain, ensuring effective delivery of the Klotho protein to targeted cells.

The treatment not only improved muscle and bone health but also stimulated the formation of new neurons and enhanced immune activity in the hippocampus, suggesting potential cognitive benefits.

In light of these findings, the research team has already patented the use of Klotho for treating cognitive deficits and has filed three new patents focused on its applications for bone and muscle deficits, as well as longevity therapies.

The researchers stress the importance of developing a viable delivery method for s-KL, which could significantly enhance the quality of life and pave the way for future longevity therapies.

The study highlights the challenges of aging, such as declines in muscle and bone density, which lead to increased frailty and cognitive decline, underscoring the urgent need for effective age-related therapies.

Treated mice displayed larger muscle fibers, reduced fibrosis, and improved bone quality, particularly in females, indicating a protective effect against osteoporosis.

The gene therapy approach involved administering viral vectors that introduce the gene for s-KL into cells, enabling them to produce the protein independently, which is crucial for the observed health benefits.